MACE (OR: 0.29 and 95% CI: 0.22–0.38) and HF (OR: 0.66 and 95% CI: 0.52–0.83) risks were lower in the SGLT2 inhibitor group than in the control group, whereas no significant difference was observed between the two groups regarding MI risk (OR: 0.32 and 95% CI: 0.02–5.49) (Figures 1g, 1h, and 1i). This evidence concerns the gene SLC5A2 and hydrops fetalis.